



phi

PHASE
HOLOGRAPHIC
IMAGING

PHI changes the date for publication of Interim Report 3 2021/22

Phase Holographic Imaging changes the date for publication of Interim Report 3 2021/22 to March 21, 2022. The reason for the change of date is to allow management and staff to participate in the newly decided rights issue by purchasing shares.

According to current regulations, insiders are prevented from trading in the company's share 30 days before publication of a report. The record date for the rights issue is March 24. Jointly, this means that acquisitions of shares over the market need to be completed on March 21 after publication or no later than March 22 to be able to subscribe with the support of unit rights in the forthcoming rights issue.

For additional information, please contact:

Peter Egelberg

E-mail: ir@phiab.se

Web: www.phiab.com – Live cell imaging & analysis

Phase Holographic Imaging (PHI) develops instrumentation and software for time-lapse cytometry. The products are used for long-term quantitative analysis of the dynamics of live cells, particularly significant in the research of cancer, as well as in the treatment of inflammatory and autoimmune diseases. The products are sold globally through the company's distributors. The company is based in Lund, Sweden, and in Boston, Massachusetts.